tag@treatmentactiongroup.org

HCV

Ribavirin Fact Sheet

  • Chad Cipiti
Ribavirin (RBV) is an HCV-fighting drug. RBV does not work by itself. Adding RBV to other drugs can increase the chance of being cured from HCV. In the United States, ribavirin is approved for children (3 to 18 years of age) and adults.
Read more

Hepatitis C Virus (HCV) Diagnostics Fact Sheet

  • Chad Cipiti

What is screening? Screening looks to see whether someone might have a disease. For hepatitis C virus (HCV), screening means looking for antibodies instead of the virus. What are antibodies? Antibodies are Y-shaped proteins made by a person’s immune system.…

Read more

Adherence Fact Sheet

  • Chad Cipiti

What is adherence? Adherence means sticking to something. It is often used to describe taking medicine without missing doses for as long as needed. Good adherence helps to maintain—or improve—your health. This fact sheet is about adherence to hepatitis C…

Read more

Olysio Fact Sheet

  • Chad Cipiti
Olysio (simeprevir) is an HCV-fighting drug. It must be used with other drugs to treat hepatitis C. In the United States, Olysio is approved for people with hepatitis C genotype 1 who are over 18 years old.
Read more

TAGline Fall 2015

  • Chad Cipiti
In Defense of Stringency: In response to growing public concern with health risks posed by approved drugs, a 2006 landmark report by the Institute of Medicine (IOM) argued that the U.S. Food and Drug Administration (FDA) lacks the unambiguous authority necessary to ensure the safety and efficacy of the country’s medicinal products.
Read more

Don’t forget treatment on World Hepatitis Day

  • Chad Cipiti
On World Hepatitis Day 2015, as the World Health Organization (WHO) emphasizes prevention, the International Treatment Preparedness Coalition (ITPC) and Treatment Action Group urge pharmaceutical companies and the governments of middle-income countries to act now to facilitate access to treatment for all people with hepatitis C virus (HCV), to avoid needless deaths from HCV complications and to prevent new infections.
Read more

2015 Pipeline Report

  • Chad Cipiti
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.
Read more

Gilead: Stop Blocking Access to Hepatitis C Treatment

  • Chad Cipiti
On the eve of pharmaceutical company Gilead Sciences’ annual shareholder meeting, thousands of people who have hepatitis C virus (HCV) and HCV/HIV coinfection, with their allies and physicians, have demanded that Gilead change its policies that deny access to treatment for millions of people in developing countries.
Read more

C U L8ter: Hepatitis C Eradication

  • Chad Cipiti

Hepatitis C is now curable. Now all we need is surveillance to monitor it, global funding to fight it, and targets set to address it By Tracy Swan The first global targets for eliminating hepatitis C virus (HCV) will be…

Read more

On Targets and Timelines

  • Chad Cipiti

By Tim Horn With growing recognition that science and discovery have forged the tools necessary to effectively diagnose, treat, and, indeed, eliminate three of the world’s most lethal infectious diseases—HIV/AIDS, tuberculosis, and hepatitis C—there is a need for greater mobilization…

Read more
Back To Top